Myeloma clinical trials

Explore recruiting myeloma clinical trials.

Recruiting myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

France, Spain, Netherlands, Greece, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma CARTITUDE-2

Spain, Netherlands, Germany, France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma

Netherlands, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)

Italy, France, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1b/2a Multicenter, Open-label, Dose Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma

France, Italy, Spain, Germany, Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Myeloma trials by city

Myeloma in Toronto Myeloma in Vancouver Myeloma in Montreal Myeloma in Calgary Myeloma in Edmonton Myeloma in Ottawa Myeloma in Winnipeg Myeloma in Quebec City Myeloma in Hamilton Myeloma in Kitchener Myeloma in London Myeloma in Halifax Myeloma in New York Myeloma in Los Angeles Myeloma in Chicago Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease